Objective: The objective of this study is to systematically review the economic evaluations of
dapagliflozin in the treatment of patients with heart failure (HF) and describe their general …

Objectives This study was aimed to systematically review published economic studies to
determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard …

Background Dapagliflozin is an antidiabetic medication that has been shown to reduce the
risk of heart failure hospitalization and cardiovascular death in patients with heart failure with …

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure
(HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This …

Background: Heart failure (HF) is a major cause of recurrent hospitalization and death
worldwide. Sodium-glucose cotransporter-2 inhibitors including dapagliflozin are anti …

Aim We aim to determine the cost‐effectiveness of dapagliflozin in addition to standard
therapy versus standard therapy alone among patients with heart failure with reduced …

Importance In the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure
(DAPA-HF) trial, dapagliflozin was shown to reduce cardiovascular mortality and …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background Several clinical trials of dapagliflozin in patients with type 2 diabetes mellitus
(T2DM) at elevated cardiovascular risk have observed reduced hospitalization for heart …

Importance Heart failure with reduced ejection fraction produces substantial morbidity,
mortality, and health care costs. Dapagliflozin is the first sodium-glucose cotransporter 2 …